Shimadzu: Measuring Alzheimer’s with trace blood: Signs of dementia
-Nobel Prize, Koichi Tanaka’s technical utilization-
Shimadzu:
June 22, Candidates for Alzheimer’s disease,
A device that measures from a small amount of blood has been released for domestic testing institutions.
Nobel Laureate in Chemistry:
Executive Research Fellow:
The analysis method developed by Koichi Tanaka was used.
Measurement of candidate causative substances for Alzheimer’s disease from trace amounts of blood
What is Alzheimer’s?
Alzheimer’s is said to account for nearly 70% of dementia.
Amyloid beta has accumulated in the brain 20 years before the onset.
afterwards,
Abnormal tau protein is generated,
Nerve cells die,
It is believed that cognitive function declines.
Measuring amyloid beta:
Measure the substances associated with the protein “amyloid beta”.
“Amyloid MS CL” released:
“Amyloid MS CL” utilizes a method of ionizing proteins and analyzing their structures.
The “amyloid peptide” contained in the blood collected from the subject is measured with a mass spectrometer.
Measured with a mass spectrometer:
Conventionally
To check for “amyloid peptide” accumulation
Use PET equipment or
It was necessary to collect cerebrospinal fluid.
By only measuring blood, the cost and burden on the subject can be reduced.
Kyoto Shimbun